Send a textWhat makes Switzerland a compelling first-launch market for Pharma? How does its healthcare system compare to other European countries? What do manufacturers need to know about reimbursement, pricing, and evidence requirements? How might the evolving Joint Clinical Assessment (JCA) landscape influence launch sequencing?This episode explores Switzerland’s potential as an early launch market.In this session, Louise Maddison (Senior Consultant – Global Pricing and Market Access, Petauri Evidence) interviewed Dr Elisabeth Brock (Independent expert in market access in Switzerland), who has extensive experience in Swiss healthcare, including regulatory and payer engagement, dossier preparation for the Swiss Specialities List (SL), and strategic launch planning.Together, we explored what global market access teams need to know about launching in Switzerland – from regulatory routes and pricing frameworks to the nuances of payer expectations and evidence generation.We discussed:- What makes Switzerland attractive as a first-launch market - Key differences between Swiss and European Union (EU) market access pathways - How to prepare for inclusion on the SL and what “economically efficient pricing” really means - The role of cantonal (state) variation and decentralised healthcare in shaping access - How Swiss decisions may be influenced by the EU’s JCA - What global teams can learn from Swiss strategy to inform broader launch planningThis episode was first broadcast as a live webinar on Thursday 16th October 2025Learn more at https://petauri.com/insights/market-access-switzerland/Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related